Tissue factor pathway inhibitor and P-selectin as markers of sepsis-induced non-overt disseminated intravascular coagulopathy

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 1, 2011, Pages 80-87

  Mosad, Eman ^a   Elsayh, Khalid I ^b   Eltayeb, Azza A ^b  

^a Assiut University Faculty of Medicine   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

non overt DIC; P selectin; pediatric sepsis; tissue factor pathway inhibitor

Indexed keywords

D DIMER; FIBRINOGEN; PADGEM PROTEIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; CHILD; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; THROMBOCYTE COUNT;

BIOLOGICAL MARKERS; CHILD, PRESCHOOL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFANT; INTENSIVE CARE UNITS; LIPOPROTEINS; MALE; P-SELECTIN; SEPSIS;

EID: 78651391841     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609344981     Document Type: Article

References (54)

1. Talmor M., Hydo L., Barie PS Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: effect of intensive care unit resuscitation. Arch Surg. 1999 ; 134 (1). 81-87.
2. Rangel-Frausto MS Sepsis: still going strong. Arch Med Res. 2005 ; 36 (6). 672-681.
3. Raghavan M., Marik PM Management of sepsis during the early ''golden hours. '' J Emerg Med. 2006 ; 31 (2). 185-199.
4. Franchini M., Veneri D., Lippi G. Inflammatioon and hemostasis: a bidirectional interaction. Clin Lab. 2007 ; 53 (1-2). 63-67.
5. Zeerleder S., Schroeder V., Lämmle B., Wuillemin WA, Hack CE, Kohler HP Factor XIII in severe sepsis and septic shock. Thromb Res. 2007 ; 119 (3). 311-318.
6. Chu AJ Tissue factor mediates inflammation. Arch Biochem Biophys. 2005 ; 440 (2). 123-132.
7. Macfarlane SR, Seatter MJ, Kanke T., Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001 ; 53 (2). 245-282.
8. Théorêt JF, Chahrour W., Yacoub D., Merhi Y. Recombinant P-selectin glycoprotein-ligand-1 delays thrombin induced platelet aggregation: a new role for P-selectin in early aggregate. Br J Pharmacol. 2006 ; 148 (3). 299-305.
9. Liaw PC, Esmon CT, Kahnamoui K., et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood. 2004 ; 104 (13). 3958-3964.
10. ten Cate H., Bauer KA, Levi M., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993 ; 92 (3). 1207-1212.
11. Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiological role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A. 1991 ; 88 (3). 708-712.
12. Ariëns RA, Alberio G., Moia M., Mannucci PM Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost. 1999 ; 81 (2). 203-207.
13. Kaiser B., Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost. 1996 ; 76 (4). 615-620.
14. Wada H., Wakita Y., Nakase T., et al. and the Mie DIC Study Group. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Hemost. 1995 ; 74 (3). 848-852.
15. Kinasewitz GT, Zein JG, Lee GL, Nazir SA, Taylor FB Jr. Prognostic value of a simple evolving DIC score in patients with severe sepsis. Crit Care Med. 2005 ; 33 (10). 2214-2221.
16. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure. Crit Care Med. 2005 ; 33 (2). 341-348.
17. Zygun D., Berthiaume L., Laupland K., Kortbeek J., Doig C. SOFA is superior to MOD score for the determination of non-neurologic organ dysfunction in patients with severe traumatic brain injury: a cohort study. Crit Care. 2006 ; 10 (4). R115.
18. Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest. 1987 ; 79 (6). 1874-1878.
19. Quick AJ, Hussey CG Interpretation of the one-stage method for determining prothrombin time. N Engl J Med. 1953 ; 248 (15). 624-628.
20. Taylor FB Jr, Toh CH, Hoots WK, Wada H., Levi M., and the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 ; 86 (5). 1327-1330.
21. Toh CH, Hoots WK The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost. 2007 ; 5 (3). 604-606.
22. Toh CH, Downey C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul Fibrinolysis. 2005 ; 16: 69-74.
23. Dellinger RP Inflammation and coagulation: implication for the septic patient. Clin Infect Dis. 2003 ; 36 (10). 1259-1265.
24. Lorente JA, García-Frade LJ, Landín L., et al. A time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest. 1993 ; 103 (5). 1536-1542.
25. Key NS, Slungaard A., Dandelet L., et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 1998 ; 91 (11). 4216-4223.
26. Moldow CF, Bach RR, Staskus K., Rick PD Induction of endothelial tissue factor by endotoxin and its precursors. Thromb Haemost. 1993 ; 70 (4). 702-706.
27. Giyette RE Hematology: a comprehensive guide to diagnosis and treatment of blood disorders. Haematologica. 1997 ; 82 (1). 57-63.
28. Iversen N., Strekerud FG, Abildgaard U. Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex. Blood Coagul Fibrinolysis. 2000 ; 11 (7). 591-598.
29. Bajaj MS, Rana SV, Wysolmerski RB, Bajai SP Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J Clin Invest. 1987 ; 79 (6). 1874-1878.
30. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patients samples. Blood. 1991 ; 78 (2). 387-393.
31. Sandset PM, Roise O., Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis. 1989 ; 19 (4). 189-195.
32. Takahashi H., Sate N., Shibata A. Plasma tissue factor pathway inhibitor in disseminated intravascular coagulation: comparison of its behavior with plasma tissue factor. Thromb Res. 1995 ; 80 (4). 339-348.
33. Carr C., Bild GS, Chang AC, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock. 1994 ; 44 (3). 126-137.
34. Camerota AJ, Creasey AA, Patla V., Larkin VA, Fink MP Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis. 1998 ; 177 (3). 668-676.
35. de Jonge E., Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000 ; 95 (4). 1124-1129.
36. Sabharwal AK, Bajaj SP, Ameri A., et al. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med. 1995 ; 151 (3 pt 1). 758-767.
37. Bajaj MS, Tricomi SM Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome. Intensive Care Med. 1999 ; 25 (11). 1259-1266.
38. Gando S., Nanzaki S., Morimoto Y., Ishitani T., Kemmotsu O. Tissue factor pathway inhibitor response does not correlate with tissue factor induced disseminated intravascular coagulation and multiple organ dysfunction syndrome in trauma patients. Crit Care Med. 2001 ; 29 (2). 262-266.
39. Gando S., Kameue T., Morimoto Y., Matsuda N., Hayakawa M., Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med. 2002 ; 30 (8). 1729-1734.
40. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis. 1995 ; 6 (suppl 1). S7 - S13.
41. Belaaouaj AA, Li A., Wun TC, Welgus HG, Shapiro SD Matrix metalloproteinases cleave tissue factor pathway inhibitor: effects on coagulation. J Biol Chem. 2000 ; 275 (35). 27123-27128.
42. Gando S., Kameue T., Matsuda N., et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res. 2003 ; 109 (2-3). 119-124.
43. Palabrica T., Lobb R., Furie BC, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992 ; 359 (6398). 848-851.
44. Furie B. P-selectin and blood coagulation: it's not only about inflammation any more. Arterioscler Thromb Vasc Biol. 2005 ; 25 (5). 877-878.
45. Wang WS, Lin JK, Lin TC, et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol. 2005 ; 11 (14). 6072-6073.
46. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996 ; 97 (6). 1525-1534.
47. Okabayashi K., Wada H., Ohta S., Shiku H., Nobori T., Maruyama K. Hemostatic markers and the sepsis-related organ failure assessment score in patients with disseminated intravascular coagulation in an intensive care unit. Am J Hematol. 2004 ; 76 (3). 225-229.
48. Gando S., Kameue T., Nanzaki S., Hayakawa T., Nakanishi Y. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory response syndrome. Crit Care Med. 1997 ; 25 (11). 1820-1826.
49. Pelzer H., Schwarz A., Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbant assay. Thromb Haemost. 1987 ; 59 (1). 101-106.
50. Kienast J., Thompson SG, Raskino C., et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complexes in patients with angina pectoris: relations to the presence and severity of coronary atherosclerosis. Thromb Haemost. 1993 ; 70 (4). 550-553.
51. Wada H., Sakuragawa N., Mori Y., et al. Haemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol. 1999 ; 60 (4). 273-278.
52. Fourrier F., Chopin C., Goudemand J., et al. Septic shock, multiple organ failure, and dissiminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992 ; 101 (3). 816-823.
53. Ferreira FL, Bota DP, Bross A., Mélot C., Vincent JL Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA. 2001 ; 286 (14). 1756-1758.
54. Moreno R., Vincent JL, Matos A., et al., and the Working Group on Sepsis Related Problems of the ESICM. The use of maximum SOFA scores to quantify organ dysfunction/ failure in intensive care: results of a prospective, multicentre study. Intensive Care Med. 1999 ; 25 (7). 686-696.